GLP-1 & Weight Management

Research peptides for metabolic and weight management studies including GLP-1 receptor agonists, dual and triple agonists, and metabolic modulators.

22 products found

Sort by:

99.4% Purity

In Stock

T -GLP-1 (10)

First-in-class synthetic 39-amino acid dual GIP/GLP-1 receptor agonist ('twincretin') with imbalanced receptor binding profile and biased signaling at GLP-1R
FDA-approved May 2022 (Mounjaro for T2D), November 2023 (Zepbound for obesity), December 2024 (Zepbound for OSA) — extensively validated in 2,000+ peer-reviewed publications
Engineered with 2 Aib residues (DPP-4 resistance), C20 fatty diacid albumin-binding moiety (5-day half-life), enabling once-weekly dosing; cryo-EM structures elucidated for both GIPR-Gs and GLP-1R-Gs complexes

$99.00

99.4% Purity

In Stock

T -GLP-1 (15mg)

First-in-Class Dual GIP/GLP-1 Receptor Agonist: 39aa twincretin with imbalanced dual agonism favoring GIPR, biased GLP-1R signaling (cAMP > beta-arrestin), FDA-approved Mounjaro (T2D 2022)/Zepbound (obesity 2023), 3,000+ publications
Unprecedented Weight Loss Efficacy: SURMOUNT-1 (Jastreboff et al., 2022, NEJM): 22.5% mean body weight reduction at 72 weeks, 39.7% participants achieved ≥25% loss, SURMOUNT-5 superior to semaglutide
Clinical Status: SURPASS-CVOT cardiovascular non-inferiority vs dulaglutide with 16% lower all-cause mortality (HR 0.84), SUMMIT trial 38% reduction CV death/worsening HF in HFpEF+obesity (HR 0.62), SYNERGY-NASH 73.3% MASH resolution at 15mg

$129.00

99.4% Purity

In Stock

T -GLP-1 (30mg)

First-in-class synthetic 39-amino acid dual GIP/GLP-1 receptor agonist ('twincretin') with imbalanced receptor binding profile and biased signaling at GLP-1R
FDA-approved May 2022 (Mounjaro for T2D), November 2023 (Zepbound for obesity), December 2024 (Zepbound for OSA) — extensively validated in 2,000+ peer-reviewed publications
Engineered with 2 Aib residues (DPP-4 resistance), C20 fatty diacid albumin-binding moiety (5-day half-life), enabling once-weekly dosing; cryo-EM structures elucidated for both GIPR-Gs and GLP-1R-Gs complexes

$199.00

99.4% Purity

In Stock

T -GLP-1 (60mg)

First-in-class synthetic 39-amino acid dual GIP/GLP-1 receptor agonist ('twincretin') with imbalanced receptor binding profile and biased signaling at GLP-1R
FDA-approved May 2022 (Mounjaro for T2D), November 2023 (Zepbound for obesity), December 2024 (Zepbound for OSA) — extensively validated in 2,000+ peer-reviewed publications
Engineered with 2 Aib residues (DPP-4 resistance), C20 fatty diacid albumin-binding moiety (5-day half-life), enabling once-weekly dosing; cryo-EM structures elucidated for both GIPR-Gs and GLP-1R-Gs complexes

$320.00

99.4% Purity

In Stock

Tirzepatide (15mg)

Tirzepatide (LY3298176) is a first-in-class 39-amino acid dual GIP/GLP-1 receptor agonist ("twincretin") with imbalanced agonism favoring GIPR over GLP-1R
Features Aib residues at positions 2 and 13 (DPP-4 resistance), C20 fatty diacid at Lys20 (albumin binding, ~5-day half-life), and biased GLP-1R signaling favoring cAMP over beta-arrestin recruitment
FDA-approved as Mounjaro (T2D, May 2022) and Zepbound (obesity, Nov 2023)

$129.00

99.4% Purity

In Stock

Tirzepatide (30mg)

First-in-Class Dual GIP/GLP-1 Agonist: 39-amino acid synthetic peptide (LY3298176), Eli Lilly design, imbalanced dual agonism (GIPR>GLP-1R), biased GLP-1R signaling (cAMP>beta-arrestin), 3,000+ publications, ~5-day half-life via C20 fatty diacid albumin binding
Unprecedented Metabolic Effects: HbA1c reduction 1.24-2.58%, 22.5% mean weight loss at 15mg (SURMOUNT-1), weight-independent insulin sensitization via GIPR, BCAA catabolism, central appetite suppression
Clinical Status: FDA-approved Mounjaro (T2D, May 2022), Zepbound (obesity, Nov 2023), OSA (Dec 2024); SURPASS-CVOT 38% reduction CV death/HF events, SYNERGY-NASH 73.3% MASH resolution

$199.00

99.4% Purity

In Stock

Tirzepatide (60mg)

First-in-class synthetic 39-amino acid dual GIP/GLP-1 receptor agonist ('twincretin') with imbalanced receptor binding profile and biased signaling at GLP-1R
FDA-approved May 2022 (Mounjaro for T2D), November 2023 (Zepbound for obesity), December 2024 (Zepbound for OSA) — extensively validated in 2,000+ peer-reviewed publications
Engineered with 2 Aib residues (DPP-4 resistance), C20 fatty diacid albumin-binding moiety (5-day half-life), enabling once-weekly dosing; cryo-EM structures elucidated for both GIPR-Gs and GLP-1R-Gs complexes

$320.00

99.4% Purity

In Stock

Retatrutide (20mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$199.00

99.4% Purity

In Stock

Retatrutide (40mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$329.00

99.4% Purity

In Stock

Retatrutide (5mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$69.00

99.4% Purity

In Stock

Reta (10mg)

First-in-Class Triple Agonist: 39 aa peptide simultaneously activating GIPR (EC₅₀ 0.0643 nM), GLP-1R (EC₅₀ 0.775 nM), GCGR (EC₅₀ 5.79 nM), GIP backbone with Aib/C20 fatty diacid, t½ 6 days, once-weekly
Superior Efficacy: Phase 2 obesity 24.2% weight loss at 48 weeks (12 mg), MASLD 82.4% liver fat reduction, T2D HbA1c -2.02%, 100+ publications, 100% ≥5% weight loss responders
Clinical Development: Phase 3 TRIUMPH program (5,800+ participants), TRIUMPH-4 showed 26.4-28.7% weight loss at 68 weeks, TRANSCEND cardiovascular outcomes program, dose-dependent GI AEs

$0.00

99.4% Purity

In Stock

Cagrilintide (10mg)

Cagrilintide - Long-acting amylin analog activating AMY1R/AMY2R/AMY3R and CALCR receptors
≥98% purity (HPLC)
Half-life 159-195 hours

$99.00